Search Results
Your search for ,WHo matches 20376 pages
Showing 10351 - 10400Report Outlines Cancer Risk Among Hispanics/Latinos in the United States
The cancer burden in Puerto Rico, a U.S. territory with a 99% Hispanic population, is substantially different from that of Hispanics in the continental United States, according to Cancer Statistics for Hispanics/Latinos, 2018. The report, published every 3 years, found that men in Puerto Rico...
Adding Lomustine to Conventional Chemotherapy in Older Patients With AML Without Unfavorable Cytogenetics
As reported in the Journal of Clinical Oncology by Pigneux et al, a French phase III trial (LAM-SA 2007 FILO) has shown an overall survival benefit with the addition of lomustine to conventional chemotherapy in older patients with acute myeloid leukemia (AML) without unfavorable cytogenetics....
Cognitive Outcomes Among Older Survivors of Breast Cancer
In a study (Thinking and Living with Cancer) reported in the Journal of Clinical Oncology, Mandelblatt et al found that poorer cognitive function in older survivors of breast cancer was associated with chemotherapy, hormone therapy, and ApoE genotype. The ApoE ε4 allele has been associated...
A Pathologic Fascination With Humanity
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Johns Hopkins Radiation Oncology Pioneer, Moody Wharam, Jr, MD, Dies at 77
MOODY WHARAM, JR, MD, Professor Emeritus of Radiation Oncology and Molecular Radiation Sciences and former Willard and Lillian Hackerman Professor of Radiation Oncology at the Johns Hopkins Kimmel Cancer Center, died on August 10 at the age of 77. Dr. Wharam specialized in the treatment of...
Eva Koziolek, DSc, PhD, Awarded First Free Me From Lung Cancer–IASLC Joint Fellowship Award
FREE ME FROM LUNG CANCER (FMFLC) and the International Association for the Study of Lung Cancer (IASLC) have announced the first-ever winner of the FMFLC-IASLC Foundation Joint Fellowship Award for the Early Detection of Lung Cancer. The FMFLC-IASLC Joint Fellowship Award supports novel,...
Niraparib Maintenance Therapy in Recurrent Ovarian Cancer
In a study reported in The Lancet Oncology, Amit M. Oza, MD, of the Princess Margaret Cancer Centre, University Health Network, Toronto, and colleagues found that quality of life based on patient-reported outcomes was not worsened with niraparib (Zejula) maintenance vs placebo in the phase III...
Analgesics and Ovarian Cancer Survival
In a prospective cohort study reported in The Lancet Oncology, Melissa A. Merritt, PhD, of the University of Hawaii Cancer Center’s Epidemiology Program, and colleagues found evidence that recent use of aspirin or nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) after diagnosis appears to...
Living a Purposeful Life Is My Revenge on Cancer
There is a lot of breast cancer in my family history. My mother was diagnosed with the disease at 44, and my paternal grandmother died of breast cancer when she was just 33, so I’ve always been diligent about performing breast self-exams— often weekly—to ensure that if I did get breast cancer, it...
Learning to Listen and Returning to the Art of Medicine
Bernard Lown, MD, was born in Lithuania, the son of a rabbi. He immigrated to the United States at the age of 14, where his scientific precocity bloomed. After attaining his medical degree from John Hopkins University School of Medicine, he pursued his passion of raising international awareness of...
On Aging and the Wellness Industry
Only a few centuries ago, the major source of moral and scientific authority in Western culture was religion, which requires trusting one of numerous supernatural deities. However, the presumption that medicine is based on evidence-based and peer-reviewed science is what gives it authority in...
Rucaparib for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
IN APRIL 2018, the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib (Rubraca) was granted approval for maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.1,2...
An Early Love of Literature Gives Way to a Career in Breast Cancer Research for Jennifer K. Litton, MD
Breast cancer specialist Jennifer K. Litton, MD, was born and reared in Leominster, Massachusetts, a small city in the north central part of the state. “I went to parochial schools until seventh grade and then went on to high school in Worcester. Although I enjoyed science early on, I was...
Closing the Gender Divide in Preference for Palliative Care
Eight years ago, a survey of the preferences of Dutch patients with cancer for health care found that while gender was one aspect influencing how men and women approach cancer care, it was the most important, with men, generally, regarding most care aspects as less important than women. The study...
FDA Approves Dacomitinib for Metastatic Non–Small Cell Lung Cancer
ON SEPTEMBER 27, 2018, the U.S. Food and Drug Administration (FDA) approved dacomitinib tablets (Vizimpro) for the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution...
Cleveland Clinic Researchers Receive NIH Grant to Study Cancer-Associated Thrombosis
THE NATIONAL Heart, Lung, and Blood Institute has awarded a $4.7 million grant to the Cleveland Clinic to study the prevention of cancer-associated thrombosis. The 5-year grant supports the creation of a new risk assessment tool to better predict patients with cancer who have a higher probability...
ESMO Recognizes Tony S. Mok, MD, FRCPC, FASCO, With Lifetime Achievement Award
THE EUROPEAN SOCIETY for Medical Oncology (ESMO) has recognized Tony S. Mok, MD, FRCPC, FASCO, with the ESMO Lifetime Achievement Award for his contributions in lung cancer. Dr. Mok, who is a Li Shu Fan Medical Foundation Endowed Professor and Chairman of the Department of Clinical Oncology at the ...
PCF Releases First National Report on Public Perception of Prostate Cancer in the United States
The Prostate Cancer Foundation (PCF) recently released the results of its first national public awareness report about risks, actions, and attitudes toward prostate cancer in the PCF 3P Report 2018: Public Perception of Prostate Cancer. Each year, even though more than three million men in...
Early PSA Testing Could Help Predict Prostate Cancer Among Black Men
In a study published by Preston et al in European Urology, researchers demonstrated that a baseline prostate-specific antigen (PSA) level obtained from black men between 40 and 60 years old may predict the future development of prostate cancer for years after testing. The study builds on ...
Small Study Shows Fecal Microbiota Transplantation May Help Restore Beneficial Bacteria in Patients With Cancer
Researchers have shown that autologous fecal microbiota transplantation may be a safe and effective way to help replenish beneficial gut bacteria in patients with cancer who require intense antibiotics during allogeneic hematopoietic stem cell transplantation. Their findings were published by Taur...
Neoadjuvant Paclitaxel With LCL161 in Localized Triple-Negative Breast Cancer
In a phase II study reported in the Journal of Clinical Oncology, Bardia et al evaluated the effects of adding an antagonist of inhibitor of apoptosis proteins (LCL161) to paclitaxel as neoadjuvant therapy in patients with localized triple-negative breast cancer who did or did not have a tumor...
FDA Grants Breakthrough Therapy Designation to Rucaparib in BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer
The U.S. Food and Drug Administration (FDA) recently granted Breakthrough Therapy designation to rucaparib (Rubraca) monotherapy for the treatment of adult patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer who have received at least one prior androgen...
Lack of Clinical Trial Participation and Shorter Duration of Therapy Linked to Disease Relapse in AYAs With Leukemia
Despite survival gains for children diagnosed with acute lymphoblastic leukemia (ALL), adolescents and young adults (AYAs)—those between the ages of 15 and 39—diagnosed with the disease have seen only modest improvements in survival. A study by Wolfson et al in Cancer Epidemiology,...
DNA Vaccine Leads to Immune Responses in HPV-Related Head and Neck Cancer in Small Study
A therapeutic vaccine may boost antibodies and T cells, helping them infiltrate human papillomavirus (HPV)-related head and neck cancer tumors. Researchers from the Abramson Cancer Center of the University of Pennsylvania tested the immunotherapy approach in two groups of patients with...
Long-Term Outcomes With Anti–PD-L1 Treatment in Metastatic Triple-Negative Breast Cancer
In a long-term follow-up of a phase I trial reported in JAMA Oncology, Emens et al found that single-agent atezolizumab (Tecentriq) produced enduring benefit in patients with metastatic triple-negative breast cancer after stable or responding disease and in first-line treatment. Study Details In...
Conquer Cancer Podcast Series Goes Unscripted With Doctors, Patients, and Caregivers
How do patients really feel when they are in your care? What does it feel like to cure a cancer? How are the children of oncologists affected when grief is a parent’s occupational hazard? These are the personal topics explored in the candid and inspirational mini-podcast series, Your Stories:...
Cancer.Net: Trusted Information for Patients and Caregivers, Useful Tools for Providers
Cancer.Net is ASCO’s patient information website, hosting a wealth of information and resources for people diagnosed with cancer and their families and caregivers. With information on over 120 types of cancer, visitors to the site can find medical information, tips for treatment management,...
Emerging Options and Sequencing Therapy in Relapsed Multiple Myeloma
Advances in the treatment of multiple myeloma have led to longer progression-free survival, but the majority of patients will still relapse despite newer treatments. A number of new drugs and combinations are under study in the hope of improving outcomes. “Multiple myeloma is a complex disease...
Study Shows Invasive Lung Cancer Surgery Can Lead to Long-Term Opioid Use
Patients treated with more invasive surgical techniques for early-stage non–small cell lung cancer (NSCLC) are more likely to become chronic opioid users than patients treated with minimally invasive surgery, highlighting the need for additional research into how pain management after surgery ...
More to Learn About Using PARP Inhibitors for Advanced Breast Cancer With Germline BRCA Mutation
Germline mutations in the breast cancer–susceptibility genes 1 and 2 (BRCA1/2) increase the risk for cancer due to an inability to repair DNA double-strand breaks, and about 5% of patients with unselected breast cancer carry a germline BRCA mutation.1 These DNA repair–deficient tumors are...
Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome
On August 8, 2018, the CC chemokine receptor type 4 (CCR4)-directed monoclonal antibody mogamulizumab-kpkc (Poteligeo) was approved for adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy.1,2 Supporting Efficacy Data The current...
Targeting CCR4 in Cutaneous T-Cell Lymphoma: The MAVORIC Trial
The C-C chemokine receptor 4 (CCR4) is predominantly expressed in type 2 helper T (Th2) cells and regulatory T (Treg) cells.1 Under physiologic conditions and in response to its ligands, CCL17 (TARC) and CCL22 (MDC), CCR4 promotes T-cell migration to the skin.2 Of note, CCR4 is highly expressed in...
Mogamulizumab Improves Progression-Free Survival vs Vorinostat in Cutaneous T-Cell Lymphoma
As reported by Youn H. Kim, MD, of Stanford Cancer Institute, Stanford University School of Medicine, and colleagues in The Lancet Oncology, the phase III MAVORIC trial showed that the anti-C-C chemokine receptor 4 (CCR4) monoclonal antibody mogamulizumab (Poteligeo) significantly improved...
Osimertinib in First-Line Treatment of EGFR-Mutant Metastatic NSCLC
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. In April 2018, osimertinib (Tagrisso) was approved for...
Strategies for Using Anticoagulation Therapy in Patients With Cancer
Although approximately 20% to 30% of patients with cancer will develop venous thromboembolism (VTE), clinicians continue to debate strategies for pharmacologic treatment and prevention.1 At the 2018 Debates and Didactics in Hematology and Oncology Conference, held on Sea Island, Georgia, Christine...
Neuroendocrine Tumors: New Data, New Options
Because neuroendocrine tumors are not one disease but a continuum of diseases, ranging from well-differentiated tumors to poorly differentiated and small cell tumors, treatment approaches can vary greatly. At the 2018 Debates and Didactics in Hematology and Oncology conference, held on Sea Island,...
Beat AML Trial Seeking to Change Treatment Paradigm
The Beat AML Master Clinical Trial seeks to change the treatment paradigm and outcomes in acute myeloid leukemia (AML) by personalizing therapy and ultimately facilitating the approval of novel targeted agents. Co-investigator William Blum, MD, of the Winship Cancer Institute at the Emory...
Wear That White Coat—With Pride
These days it can be hard for physicians. Many in the physician workforce wonder whatever happened to the ideals and expectations that drew them to this noble profession. The genuine passion to heal the sick and infirm and in turn improve the health of the entire society The ability to touch human ...
The Relevance of the RELEVANCE Trial in Follicular Lymphoma
We have seen remarkable progress in the outcomes of patients with advanced-stage follicular lymphoma over the past 2 decades.1 Recent manuscripts and presentations describing long-term follow-up of randomized trials comparing various chemotherapy platforms (all combined with anti-CD20 antibodies)...
Update on CML: Focus on Sequential Therapy, Treatment Discontinuation, and Monitoring
Chronic myeloid leukemia (CML) is a poster child for the success of molecularly targeted therapy, with some patients appearing to be “cured” of their disease and others living for a long time after treatment with a tyrosine kinase inhibitor targeting the BCR-ABL1 protein. However, there are still...
Thermal Ablation vs Stereotactic Radiotherapy in Early-Stage NSCLC
Thermal ablation is a safe, effective treatment for early-stage non–small cell lung cancer (NSCLC), with comparable results to traditional stereotactic radiotherapy, according to a study published by Uhlig et al in the journal Radiology. The results show that ablation may be an effective ...
FDA Approves Once-Weekly Carfilzomib in Combination With Dexamethasone for Relapsed or Refractory Multiple Myeloma
Today, the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) to expand the prescribing information for carfilzomib (Kyprolis) to include a once-weekly dosing option in combination with dexamethasone (once-weekly Kd70) for patients with relapsed or...
WCLC 2018: Oncogene-Driven Patient-Caregiver Communities Creating New Paradigm for NSCLC Research
A recent review of patient-caregiver communities focused on non–small cell lung cancer (NSCLC) with genomic alterations showed that these groups are improving outcomes by supporting patients and caregivers, increasing awareness and education, and accelerating research. Patient advocate Janet...
WCLC 2018: Study Analyzes Use of Thoracic Radiotherapy for Limited-Stage SCLC
A study has demonstrated that using involved-field radiotherapy (IFRT) and irradiating postchemotherapy residual primary tumor volume for limited-stage small cell lung cancer (SCLC) did not result in increased recurrence of the cancer. Xiao Hu, MD, PhD, of the Department of Thoracic Radiotherapy,...
Cancer Vaccine Shows Clinical Benefit in Phase I Study of Patients With HER2-Positive Cancers
A preclinical study showing that a vaccination with a recombinant adenovirus expressing a truncated ErbB-2 antigen can cure advanced established murine breast cancer as well as extensive established metastatic lung cancer led to the launch of a small phase I study investigating a therapeutic cancer ...
FDA Approves Cemiplimab-rwlc for Metastatic Cutaneous Squamous Cell Carcinoma
On September 28, the U.S. Food and Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (SCC) or locally advanced cutaneous SCC who are not candidates for curative surgery or...
FDA Approves Dacomitinib for Metastatic Non–Small Cell Lung Cancer
On September 27, 2018, the U.S. Food and Drug Administration (FDA) approved dacomitinib tablets (Vizimpro) for the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution...
Health Resource Utilization and CNS Metastases in EGFR-Mutant Advanced NSCLC
In a single-center study reported in the Journal of Oncology Practice, Chooback et al found that central nervous system (CNS) metastases are frequent in patients with EGFR-mutant advanced non–small cell lung cancer (NSCLC) and are associated with increased health resource...
WCLC 2018: Smoking Cessation Services Widely Accepted During Lung Cancer Screening
A recent study found that smoking cessation services offered at the time of lung cancer screening had a high acceptance rate by current smokers. William Evans, MD, FRCPC, Professor Emeritus, McMaster University Department of Oncology, and clinical advisor, Smoking Cessation, Cancer Care Ontario,...
WCLC 2018: Outdoor Air Pollution Exposure and Lung Cancer in Female Never-Smokers
Findings from a recent study demonstrate that female patients with lung cancer who have never smoked have significantly greater exposure rates to outdoor air pollution than female patients with lung cancer who have a history of smoking. Renelle L. Myers, MD, FRCPC, of the British Columbia Cancer...
